VBI Vaccines (VBIV)

Company Profile

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.

Company profile

Ticker

VBIV

Exchange

NASDAQ

Website

www.vbivaccines.com

CEO

Jeffrey R. Baxter

Incorporated

British Columbia, Canada

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.

SEC CIK

0000764195

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

VBI Vaccines (Delaware) Inc. • SciVac Ltd. • Variation Biotechnologies (US), Inc. • Variation Biotechnologies Inc. • SciVac Hong Kong Limited ...

VBIV stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Entry into a Material Definitive Agreement

29 Nov 23

8-K

Regulation FD Disclosure

20 Nov 23

8-K

VBI Vaccines Reports Third Quarter 2023 Financial Results

14 Nov 23

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

3 Nov 23

8-K

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

26 Oct 23

8-K

Regulation FD Disclosure

27 Sep 23

8-K

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

7 Sep 23

8-K

Regulation FD Disclosure

14 Aug 23

Latest ownership filings

View all

SC 13D/A

PERCEPTIVE ADVISORS LLC

Francisco Diaz-Mitoma

28 Jul 23

STEVEN GILLIS

28 Jul 23

Financial summary

Financial statements Chart VBIV financial data

Quarter (USD)	Sep 23	Jun 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2023

VBIV institutional ownership history Ownership history

64.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	43	93	-53.8%
Opened positions	4	2	+100.0%
Closed positions	54	23	+134.8%
Increased positions	1	19	-94.7%
Reduced positions	37	33	+12.1%

13F shares	Current	Prev Q	Change
Total value	6.73 bn	26.69 bn	-74.8%
Total shares	15.17 mm	104.69 mm	-85.5%
Total puts	0.00	7.80 k	EXIT
Total calls	0.00	84.70 k	EXIT
Total put/call ratio	–	0.1	–

Largest owners	Shares	Value	Change
Arch Venture Fund Vi	13.03 mm	$15.96 mm	0.0%
Perceptive Advisors	1.38 mm	$4.54 bn	-97.4%
BLK Blackrock	112.15 k	$368.96 mm	-99.1%
Cambridge Investment Research Advisors	100.37 k	$330.00 k	-96.9%
Millennium Management	89.21 k	$293.48 mm	NEW
MS Morgan Stanley	77.98 k	$256.55 mm	-73.8%
Geode Capital Management	67.19 k	$221.05 mm	-98.3%
Vanguard	62.63 k	$206.06 mm	-97.6%
GAM General American Investors	62.58 k	$205.90 mm	-96.7%
Y-Intercept	39.77 k	$130.85 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Perceptive Advisors	1.38 mm	-50.95 mm	-97.4%
BLK Blackrock	112.15 k	-12.67 mm	-99.1%
STT State Street	30.05 k	-3.89 mm	-99.2%
Geode Capital Management	67.19 k	-3.83 mm	-98.3%
Cambridge Investment Research Advisors	100.37 k	-3.12 mm	-96.9%
Vanguard	62.63 k	-2.60 mm	-97.6%
GAM General American Investors	62.58 k	-1.81 mm	-96.7%
NTRS Northern Trust	15.62 k	-1.57 mm	-99.0%
Charles Schwab Investment Management	26.38 k	-1.42 mm	-98.2%
Renaissance Technologies	0.00	-799.40 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VBIV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jul 23	Mazaltov Avi	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.3	52,500	68.25 k	52,500
27 Jul 23	Steven Gillis	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.3	52,500	68.25 k	52,500
27 Jul 23	John Robert Dillman	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.3	52,500	68.25 k	52,500
27 Jul 23	Blaine H. McKee	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.3	35,000	45.50 k	35,000
27 Jul 23	Anderson David Evander	Option (Right to Buy Common Shares) Common Shares	Grant	Acquire A	No	No	1.3	52,500	68.25 k	52,500